Immutep's TACTI-004 Trial Enrolls 50% of Targeted Patients for 1L NSCLC Treatment

Immutep has achieved 50% of its target patient enrollment in the TACTI-004 Phase III trial, a registrational trial for first-line non-small cell lung cancer. The trial, which evaluates eftilagimod alfa in combination with MSD's KEYTRUDA and chemotherapy, has enrolled 378 patients globally. The futility analysis and completion of patient enrollment remain on track for the first quarter and third quarter of CY2026, respectively.